IBSS Biomed S.A.   Report issue

For profit Phase 3
Founded: Krakow Poland (1945)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2009
NCT01993524
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IBSS Biomed S.A.

Active Ingredients

Drugs in Phase 3 Trials (2)

diphtheria toxoid (1 trial)

tetanus toxoid (1 trial)

Drugs in Other Trials (1)

lactobacillus delbrueckii (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3